[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fG7tHRm8d23KHMXyz9_RpGEa1hXxtzg5aT3wm5MgbkGk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":36,"phaseBuckets":37,"rows":44},"French National Agency for Research on AIDS and Viral Hepatitis",[4],91,false,0,36,71090,17,[13,16,19,22,25,28,31,34],{"name":14,"count":15},"HIV Infections",54,{"name":17,"count":18},"HIV Infection",13,{"name":20,"count":21},"Tuberculosis",8,{"name":23,"count":24},"Hepatitis C, Chronic",6,{"name":26,"count":27},"Chronic Hepatitis C",5,{"name":29,"count":30},"AIDS",4,{"name":32,"count":33},"Herpes Genitalis",3,{"name":35,"count":33},"HIV-Associated Lipodystrophy Syndrome",[],[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,84,106,125,153,171,189,283,371,426,476,502,530,552,580,612,634,656,692,716,734,761,779,797,815,833,851,869,892,910,928,951,969,987,1005,1031,1049,1076,1094,1112,1137,1155,1179,1202,1220,1246,1264,1289,1314,1332,1350,1368,1391,1409,1436,1454,1489,1516,1546,1569,1592,1616,1634,1652,1678,1696,1714,1732,1756,1779,1797,1820,1844,1862,1887,1912,1930,1948,1971,1989,2007,2025,2043,2061,2079,2105,2123,2146,2164,2182,2200,2223,2241,2266,2284,2302,2320,2343,2366,2384,2406,2456,2482,2505,2523,2549,2574,2597,2615,2633,2656,2679],{"intervention":46,"totalTrials":47,"cells":48},"non-nucleoside reverse transcriptase inhibitors",2,{"EARLY_PHASE1":49,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":57,"NA":82},{"trials":50,"activeCount":8},[],{"trials":52,"activeCount":8},[],{"trials":54,"activeCount":8},[],{"trials":56,"activeCount":8},[],{"trials":58,"activeCount":8},[59,71],{"nctId":60,"briefTitle":61,"status":62,"phases":63,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":68},"NCT00122668","Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients","TERMINATED",[42],"2005-07","2003-11",112,[14,35],[46,69,70],"nucleoside reverse transcriptase inhibitors","protease inhibitor",{"nctId":72,"briefTitle":73,"status":62,"phases":74,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":80},"NCT00122655","Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy",[42],"2005-06","2001-01",100,[14,79],"HIV Lipodystrophy Syndrome",[46,69,81],"protease inhibitors",{"trials":83,"activeCount":8},[],{"intervention":69,"totalTrials":47,"cells":85},{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":94,"NA":104},{"trials":87,"activeCount":8},[],{"trials":89,"activeCount":8},[],{"trials":91,"activeCount":8},[],{"trials":93,"activeCount":8},[],{"trials":95,"activeCount":8},[96,100],{"nctId":60,"briefTitle":61,"status":62,"phases":97,"completion":64,"start":65,"enrollment":66,"conditions":98,"interventions":99},[42],[14,35],[46,69,70],{"nctId":72,"briefTitle":73,"status":62,"phases":101,"completion":75,"start":76,"enrollment":77,"conditions":102,"interventions":103},[42],[14,79],[46,69,81],{"trials":105,"activeCount":8},[],{"intervention":70,"totalTrials":107,"cells":108},1,{"EARLY_PHASE1":109,"PHASE1":111,"PHASE2":113,"PHASE3":115,"PHASE4":117,"NA":123},{"trials":110,"activeCount":8},[],{"trials":112,"activeCount":8},[],{"trials":114,"activeCount":8},[],{"trials":116,"activeCount":8},[],{"trials":118,"activeCount":8},[119],{"nctId":60,"briefTitle":61,"status":62,"phases":120,"completion":64,"start":65,"enrollment":66,"conditions":121,"interventions":122},[42],[14,35],[46,69,70],{"trials":124,"activeCount":8},[],{"intervention":126,"totalTrials":107,"cells":127},"Pravastatin",{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":151},{"trials":129,"activeCount":8},[],{"trials":131,"activeCount":8},[],{"trials":133,"activeCount":8},[],{"trials":135,"activeCount":8},[],{"trials":137,"activeCount":8},[138],{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"NCT00117494","Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)","COMPLETED",[42],"2007-03","2007-06","2005-10",86,[148,14],"Hyperlipidemia",[126,150],"Rosuvastatin",{"trials":152,"activeCount":8},[],{"intervention":150,"totalTrials":107,"cells":154},{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":161,"PHASE4":163,"NA":169},{"trials":156,"activeCount":8},[],{"trials":158,"activeCount":8},[],{"trials":160,"activeCount":8},[],{"trials":162,"activeCount":8},[],{"trials":164,"activeCount":8},[165],{"nctId":139,"briefTitle":140,"status":141,"phases":166,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":167,"interventions":168},[42],[148,14],[126,150],{"trials":170,"activeCount":8},[],{"intervention":81,"totalTrials":107,"cells":172},{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":179,"PHASE4":181,"NA":187},{"trials":174,"activeCount":8},[],{"trials":176,"activeCount":8},[],{"trials":178,"activeCount":8},[],{"trials":180,"activeCount":8},[],{"trials":182,"activeCount":8},[183],{"nctId":72,"briefTitle":73,"status":62,"phases":184,"completion":75,"start":76,"enrollment":77,"conditions":185,"interventions":186},[42],[14,79],[46,69,81],{"trials":188,"activeCount":8},[],{"intervention":190,"totalTrials":191,"cells":192},"Ribavirin",7,{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":247,"PHASE4":279,"NA":281},{"trials":194,"activeCount":8},[],{"trials":196,"activeCount":8},[],{"trials":198,"activeCount":8},[199,210,222,236],{"nctId":200,"briefTitle":201,"status":202,"phases":203,"start":204,"enrollment":66,"conditions":205,"interventions":207},"NCT00148837","Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis","UNKNOWN",[40],"2004-09",[23,206],"Fibrosis",[208,190,209],"Peg-interferon alpha 2b","Prazosin",{"nctId":211,"briefTitle":212,"status":141,"phases":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":218},"NCT00196586","Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV\u002FHCV Coinfected Patients",[40],"2006-11","2003-04",75,[14,26],[219,220,221],"Interleukin 2","pegylated interferon alpha 2a","ribavirin",{"nctId":223,"briefTitle":224,"status":141,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":233},"NCT01463956","Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation",[40],"2014-06","2015-01-22","2012-01-06",58,[231,232],"HCV Infection","Liver Cirrhosis, Experimental",[234,235,190],"Boceprevir","Peg-Interferon α-2b or Peg-Interferon α-2a",{"nctId":237,"briefTitle":238,"status":141,"phases":239,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":244},"NCT00148863","Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C",[40],"2007-08","2004-06",65,[23],[245,190,246],"Peg-interferon alpha 2a","Interferon gamma",{"trials":248,"activeCount":8},[249,258,269],{"nctId":250,"briefTitle":251,"status":141,"phases":252,"completion":253,"start":254,"enrollment":77,"conditions":255,"interventions":256},"NCT00158496","Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)",[41],"2005-01","2002-08",[26],[257,221],"pegylated interferon alpha2a",{"nctId":259,"briefTitle":260,"status":62,"phases":261,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":266},"NCT00122629","Triple Therapy With Peg-Interferon Alfa-2b\u002FRibavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b\u002FRibavirin for Previous Hepatitis C Virus (HCV) Non Responders",[41],"2003-05","2000-10",405,[23],[267,221,268],"peg-interferon alfa-2b","amantadine",{"nctId":270,"briefTitle":271,"status":141,"phases":272,"primaryCompletion":273,"completion":273,"start":65,"enrollment":274,"conditions":275,"interventions":276},"NCT00122616","Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C",[41],"2009-03",52,[14,23],[277,190,278,278],"Peginterferon alpha-2a","HIV antiretroviral therapy",{"trials":280,"activeCount":8},[],{"trials":282,"activeCount":8},[],{"intervention":284,"totalTrials":191,"cells":285},"efavirenz",{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":315,"PHASE4":367,"NA":369},{"trials":287,"activeCount":8},[],{"trials":289,"activeCount":8},[],{"trials":291,"activeCount":8},[292,303],{"nctId":293,"briefTitle":294,"status":141,"phases":295,"completion":204,"start":296,"enrollment":297,"conditions":298,"interventions":300},"NCT00196599","Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults",[40],"1999-02",39,[14,299],"Antiretroviral Naive",[301,302,284],"emtricitabine, FTC","didanosine, ddI",{"nctId":304,"briefTitle":305,"status":141,"phases":306,"primaryCompletion":307,"completion":308,"start":309,"enrollment":274,"conditions":310,"interventions":311},"NCT00122538","Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)",[40],"2008-11","2009-05","2006-02",[14,29],[312,313,314],"Efavirenz","Lamivudine","Didanosine",{"trials":316,"activeCount":8},[317,327,337,348,356],{"nctId":318,"briefTitle":319,"status":141,"phases":320,"completion":321,"start":322,"enrollment":77,"conditions":323,"interventions":324},"NCT00158470","Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)",[41],"2007-05","2003-09",[17],[284,325,326],"didanosine","lamivudine",{"nctId":328,"briefTitle":329,"status":141,"phases":330,"completion":331,"start":241,"enrollment":332,"conditions":333,"interventions":334},"NCT00158457","Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)",[41],"2006-12",40,[17],[335,336,312],"Tenofovir","Emtricitabine",{"nctId":338,"briefTitle":339,"status":141,"phases":340,"completion":331,"start":341,"enrollment":342,"conditions":343,"interventions":344},"NCT00158405","Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)",[41],"2002-12",840,[14],[345,313,312,346,347],"Zidovudine","Ritonavir","Indinavir",{"nctId":349,"briefTitle":350,"status":141,"phases":351,"completion":204,"start":352,"enrollment":353,"conditions":354,"interventions":355},"NCT00196612","Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART",[41],"2001-04",350,[14],[301,302,284],{"nctId":357,"briefTitle":358,"status":141,"phases":359,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":364},"NCT00115609","Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)",[41],"2009-11","2006-01",70,[14,20],[284,365,366],"tenofovir DF","emtricitabine",{"trials":368,"activeCount":8},[],{"trials":370,"activeCount":8},[],{"intervention":313,"totalTrials":24,"cells":372},{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":391,"PHASE4":422,"NA":424},{"trials":374,"activeCount":8},[],{"trials":376,"activeCount":8},[],{"trials":378,"activeCount":8},[379,383],{"nctId":304,"briefTitle":305,"status":141,"phases":380,"primaryCompletion":307,"completion":308,"start":309,"enrollment":274,"conditions":381,"interventions":382},[40],[14,29],[312,313,314],{"nctId":384,"briefTitle":385,"status":62,"phases":386,"completion":387,"start":388,"enrollment":332,"conditions":389,"interventions":390},"NCT00120783","Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance",[40],"2003-08","2002-02",[14],[347,313,346],{"trials":392,"activeCount":8},[393,397,407,411],{"nctId":318,"briefTitle":319,"status":141,"phases":394,"completion":321,"start":322,"enrollment":77,"conditions":395,"interventions":396},[41],[17],[284,325,326],{"nctId":398,"briefTitle":399,"status":62,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":21,"conditions":403,"interventions":405},"NCT00120796","Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)",[41],"2008-07","2005-08",[404],"Hepatitis B",[313,406],"Recombinant hepatitis B surface antigen",{"nctId":338,"briefTitle":339,"status":141,"phases":408,"completion":331,"start":341,"enrollment":342,"conditions":409,"interventions":410},[41],[14],[345,313,312,346,347],{"nctId":412,"briefTitle":413,"status":141,"phases":414,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":420},"NCT00640263","Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir\u002FRitonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding",[41],"2013-05","2014-02","2009-12",1500,[14],[421,313],"lopinavir\u002Fritonavir",{"trials":423,"activeCount":8},[],{"trials":425,"activeCount":8},[],{"intervention":335,"totalTrials":30,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":454,"PHASE4":472,"NA":474},{"trials":429,"activeCount":8},[],{"trials":431,"activeCount":8},[],{"trials":433,"activeCount":8},[434,444],{"nctId":435,"briefTitle":436,"status":141,"phases":437,"primaryCompletion":438,"completion":417,"start":439,"enrollment":440,"conditions":441,"interventions":443},"NCT00334256","Tenofovir\u002FEmtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)",[40],"2009-07","2006-10",72,[17,442],"Pregnancy",[335,336],{"nctId":445,"briefTitle":446,"status":62,"phases":447,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":452},"NCT00122577","Efficacy and Safety of Tenofovir DF\u002FAtazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients",[40],"2004-07","2002-03",50,[14],[335,453,346],"Atazanavir",{"trials":455,"activeCount":8},[456,460],{"nctId":328,"briefTitle":329,"status":141,"phases":457,"completion":331,"start":241,"enrollment":332,"conditions":458,"interventions":459},[41],[17],[335,336,312],{"nctId":461,"briefTitle":462,"status":141,"phases":463,"primaryCompletion":464,"completion":465,"start":401,"enrollment":466,"conditions":467,"interventions":468},"NCT00573001","Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)",[41],"2011-07","2011-12",120,[14],[469,470,335,471],"Tenofovir\u002FEmtricitabine (Truvada) and Nevirapine","Tenofovir\u002FEmtricitabine\u002FEfavirenz","Tenofovir\u002FEmtricitabine (Truvada) and Zidovudine",{"trials":473,"activeCount":8},[],{"trials":475,"activeCount":8},[],{"intervention":336,"totalTrials":33,"cells":477},{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":488,"PHASE4":498,"NA":500},{"trials":479,"activeCount":8},[],{"trials":481,"activeCount":8},[],{"trials":483,"activeCount":8},[484],{"nctId":435,"briefTitle":436,"status":141,"phases":485,"primaryCompletion":438,"completion":417,"start":439,"enrollment":440,"conditions":486,"interventions":487},[40],[17,442],[335,336],{"trials":489,"activeCount":8},[490,494],{"nctId":328,"briefTitle":329,"status":141,"phases":491,"completion":331,"start":241,"enrollment":332,"conditions":492,"interventions":493},[41],[17],[335,336,312],{"nctId":357,"briefTitle":358,"status":141,"phases":495,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":496,"interventions":497},[41],[14,20],[284,365,366],{"trials":499,"activeCount":8},[],{"trials":501,"activeCount":8},[],{"intervention":257,"totalTrials":47,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":526,"NA":528},{"trials":505,"activeCount":8},[],{"trials":507,"activeCount":8},[],{"trials":509,"activeCount":8},[],{"trials":511,"activeCount":8},[512,516],{"nctId":250,"briefTitle":251,"status":141,"phases":513,"completion":253,"start":254,"enrollment":77,"conditions":514,"interventions":515},[41],[26],[257,221],{"nctId":517,"briefTitle":518,"status":141,"phases":519,"primaryCompletion":520,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":525},"NCT00158522","Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)",[41],"2007-12","2003-02",31,[524],"Hepatitis C",[257],{"trials":527,"activeCount":8},[],{"trials":529,"activeCount":8},[],{"intervention":325,"totalTrials":47,"cells":531},{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":542,"PHASE4":548,"NA":550},{"trials":533,"activeCount":8},[],{"trials":535,"activeCount":8},[],{"trials":537,"activeCount":8},[538],{"nctId":304,"briefTitle":305,"status":141,"phases":539,"primaryCompletion":307,"completion":308,"start":309,"enrollment":274,"conditions":540,"interventions":541},[40],[14,29],[312,313,314],{"trials":543,"activeCount":8},[544],{"nctId":318,"briefTitle":319,"status":141,"phases":545,"completion":321,"start":322,"enrollment":77,"conditions":546,"interventions":547},[41],[17],[284,325,326],{"trials":549,"activeCount":8},[],{"trials":551,"activeCount":8},[],{"intervention":421,"totalTrials":47,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":576,"NA":578},{"trials":555,"activeCount":8},[],{"trials":557,"activeCount":8},[],{"trials":559,"activeCount":8},[],{"trials":561,"activeCount":8},[562,572],{"nctId":563,"briefTitle":564,"status":141,"phases":565,"primaryCompletion":566,"completion":567,"start":360,"enrollment":568,"conditions":569,"interventions":570},"NCT00946595","Evaluation of a Lopinavir\u002FRitonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients",[40,41],"2013-07","2014-01",420,[14],[571,421],"efavirenz\u002Femtricitabin\u002Ftenofovir",{"nctId":412,"briefTitle":413,"status":141,"phases":573,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":574,"interventions":575},[41],[14],[421,313],{"trials":577,"activeCount":8},[],{"trials":579,"activeCount":8},[],{"intervention":581,"totalTrials":47,"cells":582},"Pioglitazone",{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":608,"NA":610},{"trials":584,"activeCount":8},[],{"trials":586,"activeCount":8},[],{"trials":588,"activeCount":8},[],{"trials":590,"activeCount":8},[591,600],{"nctId":592,"briefTitle":593,"status":62,"phases":594,"primaryCompletion":595,"completion":595,"start":596,"enrollment":332,"conditions":597,"interventions":599},"NCT00927290","Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance",[41],"2012-07-06","2009-12-03",[26,598],"Insulin Resistance",[581],{"nctId":601,"briefTitle":602,"status":62,"phases":603,"completion":604,"start":521,"enrollment":605,"conditions":606,"interventions":607},"NCT00148850","Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients",[41],"2004-10",130,[35,14],[581],{"trials":609,"activeCount":8},[],{"trials":611,"activeCount":8},[],{"intervention":301,"totalTrials":47,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":624,"PHASE4":630,"NA":632},{"trials":615,"activeCount":8},[],{"trials":617,"activeCount":8},[],{"trials":619,"activeCount":8},[620],{"nctId":293,"briefTitle":294,"status":141,"phases":621,"completion":204,"start":296,"enrollment":297,"conditions":622,"interventions":623},[40],[14,299],[301,302,284],{"trials":625,"activeCount":8},[626],{"nctId":349,"briefTitle":350,"status":141,"phases":627,"completion":204,"start":352,"enrollment":353,"conditions":628,"interventions":629},[41],[14],[301,302,284],{"trials":631,"activeCount":8},[],{"trials":633,"activeCount":8},[],{"intervention":302,"totalTrials":47,"cells":635},{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":646,"PHASE4":652,"NA":654},{"trials":637,"activeCount":8},[],{"trials":639,"activeCount":8},[],{"trials":641,"activeCount":8},[642],{"nctId":293,"briefTitle":294,"status":141,"phases":643,"completion":204,"start":296,"enrollment":297,"conditions":644,"interventions":645},[40],[14,299],[301,302,284],{"trials":647,"activeCount":8},[648],{"nctId":349,"briefTitle":350,"status":141,"phases":649,"completion":204,"start":352,"enrollment":353,"conditions":650,"interventions":651},[41],[14],[301,302,284],{"trials":653,"activeCount":8},[],{"trials":655,"activeCount":8},[],{"intervention":657,"totalTrials":47,"cells":658},"Enfuvirtide",{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":675,"PHASE4":688,"NA":690},{"trials":660,"activeCount":8},[],{"trials":662,"activeCount":8},[],{"trials":664,"activeCount":8},[665],{"nctId":666,"briefTitle":667,"status":141,"phases":668,"primaryCompletion":520,"completion":520,"start":669,"enrollment":670,"conditions":671,"interventions":673},"NCT00120367","Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)",[40],"2005-04",30,[672,14],"Leukoencephalopathy, Progressive Multifocal",[657,674],"Tenofovir-Emtricitabine",{"trials":676,"activeCount":8},[677],{"nctId":678,"briefTitle":679,"status":141,"phases":680,"primaryCompletion":417,"completion":417,"start":681,"enrollment":682,"conditions":683,"interventions":684},"NCT00302822","Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)",[41],"2006-04",195,[14,29],[685,686,687],"enfuvirtide","emtricitabine\u002Ftenofovir","lopinavir or efavirenz",{"trials":689,"activeCount":8},[],{"trials":691,"activeCount":8},[],{"intervention":693,"totalTrials":107,"cells":694},"FTC\u002FTDF + EFV or LPV\u002FR +T20",{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":701,"PHASE4":712,"NA":714},{"trials":696,"activeCount":8},[],{"trials":698,"activeCount":8},[],{"trials":700,"activeCount":8},[],{"trials":702,"activeCount":8},[703],{"nctId":704,"briefTitle":705,"status":141,"phases":706,"primaryCompletion":707,"completion":707,"start":321,"enrollment":708,"conditions":709,"interventions":710},"NCT00454337","Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load",[41],"2008-09",170,[14],[693,711],"FTC\u002FTDF + EFV or LPV\u002FR",{"trials":713,"activeCount":8},[],{"trials":715,"activeCount":8},[],{"intervention":711,"totalTrials":107,"cells":717},{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":724,"PHASE4":730,"NA":732},{"trials":719,"activeCount":8},[],{"trials":721,"activeCount":8},[],{"trials":723,"activeCount":8},[],{"trials":725,"activeCount":8},[726],{"nctId":704,"briefTitle":705,"status":141,"phases":727,"primaryCompletion":707,"completion":707,"start":321,"enrollment":708,"conditions":728,"interventions":729},[41],[14],[693,711],{"trials":731,"activeCount":8},[],{"trials":733,"activeCount":8},[],{"intervention":735,"totalTrials":107,"cells":736},"CLEVUDINE + TENOFOVIR PLACEBO",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":757,"NA":759},{"trials":738,"activeCount":8},[],{"trials":740,"activeCount":8},[],{"trials":742,"activeCount":8},[],{"trials":744,"activeCount":8},[745],{"nctId":746,"briefTitle":747,"status":62,"phases":748,"primaryCompletion":749,"completion":749,"start":749,"enrollment":750,"conditions":751,"interventions":754},"NCT00823342","ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy",[41],"2008-12-14",150,[752,753],"HBe Negative Chronic Hepatitis B","Hepatitis B Viral Infection",[735,755,756],"CLEVUDINE IN ASSOCIATION TENOFOVIR","TENOFOVIR + CLEVUDINE PLACEBO",{"trials":758,"activeCount":8},[],{"trials":760,"activeCount":8},[],{"intervention":755,"totalTrials":107,"cells":762},{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":769,"PHASE4":775,"NA":777},{"trials":764,"activeCount":8},[],{"trials":766,"activeCount":8},[],{"trials":768,"activeCount":8},[],{"trials":770,"activeCount":8},[771],{"nctId":746,"briefTitle":747,"status":62,"phases":772,"primaryCompletion":749,"completion":749,"start":749,"enrollment":750,"conditions":773,"interventions":774},[41],[752,753],[735,755,756],{"trials":776,"activeCount":8},[],{"trials":778,"activeCount":8},[],{"intervention":756,"totalTrials":107,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":793,"NA":795},{"trials":782,"activeCount":8},[],{"trials":784,"activeCount":8},[],{"trials":786,"activeCount":8},[],{"trials":788,"activeCount":8},[789],{"nctId":746,"briefTitle":747,"status":62,"phases":790,"primaryCompletion":749,"completion":749,"start":749,"enrollment":750,"conditions":791,"interventions":792},[41],[752,753],[735,755,756],{"trials":794,"activeCount":8},[],{"trials":796,"activeCount":8},[],{"intervention":267,"totalTrials":107,"cells":798},{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":803,"PHASE3":805,"PHASE4":811,"NA":813},{"trials":800,"activeCount":8},[],{"trials":802,"activeCount":8},[],{"trials":804,"activeCount":8},[],{"trials":806,"activeCount":8},[807],{"nctId":259,"briefTitle":260,"status":62,"phases":808,"completion":262,"start":263,"enrollment":264,"conditions":809,"interventions":810},[41],[23],[267,221,268],{"trials":812,"activeCount":8},[],{"trials":814,"activeCount":8},[],{"intervention":268,"totalTrials":107,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":829,"NA":831},{"trials":818,"activeCount":8},[],{"trials":820,"activeCount":8},[],{"trials":822,"activeCount":8},[],{"trials":824,"activeCount":8},[825],{"nctId":259,"briefTitle":260,"status":62,"phases":826,"completion":262,"start":263,"enrollment":264,"conditions":827,"interventions":828},[41],[23],[267,221,268],{"trials":830,"activeCount":8},[],{"trials":832,"activeCount":8},[],{"intervention":571,"totalTrials":107,"cells":834},{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":847,"NA":849},{"trials":836,"activeCount":8},[],{"trials":838,"activeCount":8},[],{"trials":840,"activeCount":8},[],{"trials":842,"activeCount":8},[843],{"nctId":563,"briefTitle":564,"status":141,"phases":844,"primaryCompletion":566,"completion":567,"start":360,"enrollment":568,"conditions":845,"interventions":846},[40,41],[14],[571,421],{"trials":848,"activeCount":8},[],{"trials":850,"activeCount":8},[],{"intervention":406,"totalTrials":107,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":865,"NA":867},{"trials":854,"activeCount":8},[],{"trials":856,"activeCount":8},[],{"trials":858,"activeCount":8},[],{"trials":860,"activeCount":8},[861],{"nctId":398,"briefTitle":399,"status":62,"phases":862,"primaryCompletion":401,"completion":401,"start":402,"enrollment":21,"conditions":863,"interventions":864},[41],[404],[313,406],{"trials":866,"activeCount":8},[],{"trials":868,"activeCount":8},[],{"intervention":870,"totalTrials":107,"cells":871},"Alendronate",{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":888,"NA":890},{"trials":873,"activeCount":8},[],{"trials":875,"activeCount":8},[],{"trials":877,"activeCount":8},[],{"trials":879,"activeCount":8},[880],{"nctId":881,"briefTitle":882,"status":141,"phases":883,"primaryCompletion":307,"completion":307,"start":604,"enrollment":884,"conditions":885,"interventions":887},"NCT00120757","Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)",[41],140,[886,14],"Osteoporosis",[870],{"trials":889,"activeCount":8},[],{"trials":891,"activeCount":8},[],{"intervention":277,"totalTrials":107,"cells":893},{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":900,"PHASE4":906,"NA":908},{"trials":895,"activeCount":8},[],{"trials":897,"activeCount":8},[],{"trials":899,"activeCount":8},[],{"trials":901,"activeCount":8},[902],{"nctId":270,"briefTitle":271,"status":141,"phases":903,"primaryCompletion":273,"completion":273,"start":65,"enrollment":274,"conditions":904,"interventions":905},[41],[14,23],[277,190,278,278],{"trials":907,"activeCount":8},[],{"trials":909,"activeCount":8},[],{"intervention":278,"totalTrials":107,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":924,"NA":926},{"trials":913,"activeCount":8},[],{"trials":915,"activeCount":8},[],{"trials":917,"activeCount":8},[],{"trials":919,"activeCount":8},[920],{"nctId":270,"briefTitle":271,"status":141,"phases":921,"primaryCompletion":273,"completion":273,"start":65,"enrollment":274,"conditions":922,"interventions":923},[41],[14,23],[277,190,278,278],{"trials":925,"activeCount":8},[],{"trials":927,"activeCount":8},[],{"intervention":929,"totalTrials":107,"cells":930},"Paroxetine",{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":947,"NA":949},{"trials":932,"activeCount":8},[],{"trials":934,"activeCount":8},[],{"trials":936,"activeCount":8},[],{"trials":938,"activeCount":8},[939],{"nctId":940,"briefTitle":941,"status":141,"phases":942,"completion":943,"start":145,"enrollment":944,"conditions":945,"interventions":946},"NCT00196664","Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin",[41],"2009-02",144,[26],[929],{"trials":948,"activeCount":8},[],{"trials":950,"activeCount":8},[],{"intervention":469,"totalTrials":107,"cells":952},{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":959,"PHASE4":965,"NA":967},{"trials":954,"activeCount":8},[],{"trials":956,"activeCount":8},[],{"trials":958,"activeCount":8},[],{"trials":960,"activeCount":8},[961],{"nctId":461,"briefTitle":462,"status":141,"phases":962,"primaryCompletion":464,"completion":465,"start":401,"enrollment":466,"conditions":963,"interventions":964},[41],[14],[469,470,335,471],{"trials":966,"activeCount":8},[],{"trials":968,"activeCount":8},[],{"intervention":470,"totalTrials":107,"cells":970},{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":983,"NA":985},{"trials":972,"activeCount":8},[],{"trials":974,"activeCount":8},[],{"trials":976,"activeCount":8},[],{"trials":978,"activeCount":8},[979],{"nctId":461,"briefTitle":462,"status":141,"phases":980,"primaryCompletion":464,"completion":465,"start":401,"enrollment":466,"conditions":981,"interventions":982},[41],[14],[469,470,335,471],{"trials":984,"activeCount":8},[],{"trials":986,"activeCount":8},[],{"intervention":471,"totalTrials":107,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":1001,"NA":1003},{"trials":990,"activeCount":8},[],{"trials":992,"activeCount":8},[],{"trials":994,"activeCount":8},[],{"trials":996,"activeCount":8},[997],{"nctId":461,"briefTitle":462,"status":141,"phases":998,"primaryCompletion":464,"completion":465,"start":401,"enrollment":466,"conditions":999,"interventions":1000},[41],[14],[469,470,335,471],{"trials":1002,"activeCount":8},[],{"trials":1004,"activeCount":8},[],{"intervention":1006,"totalTrials":107,"cells":1007},"TRUVADA",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1014,"PHASE4":1027,"NA":1029},{"trials":1009,"activeCount":8},[],{"trials":1011,"activeCount":8},[],{"trials":1013,"activeCount":8},[],{"trials":1015,"activeCount":8},[1016],{"nctId":1017,"briefTitle":1018,"status":141,"phases":1019,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1025},"NCT00391638","Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients",[40,41],"2011-05","2012-10","2007-01",56,[404,14],[1006,1026],"PEGASYS 180μg",{"trials":1028,"activeCount":8},[],{"trials":1030,"activeCount":8},[],{"intervention":1026,"totalTrials":107,"cells":1032},{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1045,"NA":1047},{"trials":1034,"activeCount":8},[],{"trials":1036,"activeCount":8},[],{"trials":1038,"activeCount":8},[],{"trials":1040,"activeCount":8},[1041],{"nctId":1017,"briefTitle":1018,"status":141,"phases":1042,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":1043,"interventions":1044},[40,41],[404,14],[1006,1026],{"trials":1046,"activeCount":8},[],{"trials":1048,"activeCount":8},[],{"intervention":1050,"totalTrials":107,"cells":1051},"Nevirapine based therapy",{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1058,"PHASE4":1072,"NA":1074},{"trials":1053,"activeCount":8},[],{"trials":1055,"activeCount":8},[],{"trials":1057,"activeCount":8},[],{"trials":1059,"activeCount":8},[1060],{"nctId":1061,"briefTitle":1062,"status":141,"phases":1063,"primaryCompletion":1064,"completion":1064,"start":520,"enrollment":1065,"conditions":1066,"interventions":1069},"NCT00495326","Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)",[40,41],"2011-04",570,[20,1067,1068],"Aids","Hiv Infections",[1050,1070,1071],"Efavirenz based therapy","Rifampicin",{"trials":1073,"activeCount":8},[],{"trials":1075,"activeCount":8},[],{"intervention":1070,"totalTrials":107,"cells":1077},{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1084,"PHASE4":1090,"NA":1092},{"trials":1079,"activeCount":8},[],{"trials":1081,"activeCount":8},[],{"trials":1083,"activeCount":8},[],{"trials":1085,"activeCount":8},[1086],{"nctId":1061,"briefTitle":1062,"status":141,"phases":1087,"primaryCompletion":1064,"completion":1064,"start":520,"enrollment":1065,"conditions":1088,"interventions":1089},[40,41],[20,1067,1068],[1050,1070,1071],{"trials":1091,"activeCount":8},[],{"trials":1093,"activeCount":8},[],{"intervention":1071,"totalTrials":107,"cells":1095},{"EARLY_PHASE1":1096,"PHASE1":1098,"PHASE2":1100,"PHASE3":1102,"PHASE4":1108,"NA":1110},{"trials":1097,"activeCount":8},[],{"trials":1099,"activeCount":8},[],{"trials":1101,"activeCount":8},[],{"trials":1103,"activeCount":8},[1104],{"nctId":1061,"briefTitle":1062,"status":141,"phases":1105,"primaryCompletion":1064,"completion":1064,"start":520,"enrollment":1065,"conditions":1106,"interventions":1107},[40,41],[20,1067,1068],[1050,1070,1071],{"trials":1109,"activeCount":8},[],{"trials":1111,"activeCount":8},[],{"intervention":1113,"totalTrials":107,"cells":1114},"Darunavir",{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1121,"PHASE4":1133,"NA":1135},{"trials":1116,"activeCount":8},[],{"trials":1118,"activeCount":8},[],{"trials":1120,"activeCount":8},[],{"trials":1122,"activeCount":8},[1123],{"nctId":1124,"briefTitle":1125,"status":141,"phases":1126,"primaryCompletion":1127,"completion":1128,"start":143,"enrollment":1129,"conditions":1130,"interventions":1131},"NCT00421551","Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136",[41],"2010-06","2011-02",225,[14],[1113,1132],"ritonavir",{"trials":1134,"activeCount":8},[],{"trials":1136,"activeCount":8},[],{"intervention":345,"totalTrials":107,"cells":1138},{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1151,"NA":1153},{"trials":1140,"activeCount":8},[],{"trials":1142,"activeCount":8},[],{"trials":1144,"activeCount":8},[],{"trials":1146,"activeCount":8},[1147],{"nctId":338,"briefTitle":339,"status":141,"phases":1148,"completion":331,"start":341,"enrollment":342,"conditions":1149,"interventions":1150},[41],[14],[345,313,312,346,347],{"trials":1152,"activeCount":8},[],{"trials":1154,"activeCount":8},[],{"intervention":1156,"totalTrials":107,"cells":1157},"Methadone",{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1164,"PHASE4":1175,"NA":1177},{"trials":1159,"activeCount":8},[],{"trials":1161,"activeCount":8},[],{"trials":1163,"activeCount":8},[],{"trials":1165,"activeCount":8},[1166],{"nctId":1167,"briefTitle":1168,"status":141,"phases":1169,"primaryCompletion":465,"completion":465,"start":1170,"enrollment":1171,"conditions":1172,"interventions":1174},"NCT00657397","Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices",[41],"2009-01",197,[524,1173,1156],"Substance Dependence",[1156],{"trials":1176,"activeCount":8},[],{"trials":1178,"activeCount":8},[],{"intervention":1180,"totalTrials":107,"cells":1181},"pentoxyphilline",{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1188,"PHASE4":1198,"NA":1200},{"trials":1183,"activeCount":8},[],{"trials":1185,"activeCount":8},[],{"trials":1187,"activeCount":8},[],{"trials":1189,"activeCount":8},[1190],{"nctId":1191,"briefTitle":1192,"status":62,"phases":1193,"completion":331,"start":388,"enrollment":77,"conditions":1194,"interventions":1196},"NCT00119119","Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C",[41],[23,1195],"Liver Fibrosis",[1180,1197],"tocopherol",{"trials":1199,"activeCount":8},[],{"trials":1201,"activeCount":8},[],{"intervention":1197,"totalTrials":107,"cells":1203},{"EARLY_PHASE1":1204,"PHASE1":1206,"PHASE2":1208,"PHASE3":1210,"PHASE4":1216,"NA":1218},{"trials":1205,"activeCount":8},[],{"trials":1207,"activeCount":8},[],{"trials":1209,"activeCount":8},[],{"trials":1211,"activeCount":8},[1212],{"nctId":1191,"briefTitle":1192,"status":62,"phases":1213,"completion":331,"start":388,"enrollment":77,"conditions":1214,"interventions":1215},[41],[23,1195],[1180,1197],{"trials":1217,"activeCount":8},[],{"trials":1219,"activeCount":8},[],{"intervention":1221,"totalTrials":107,"cells":1222},"Antiretroviral combination",{"EARLY_PHASE1":1223,"PHASE1":1225,"PHASE2":1227,"PHASE3":1229,"PHASE4":1242,"NA":1244},{"trials":1224,"activeCount":8},[],{"trials":1226,"activeCount":8},[],{"trials":1228,"activeCount":8},[],{"trials":1230,"activeCount":8},[1231],{"nctId":1232,"briefTitle":1233,"status":62,"phases":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":1238,"interventions":1240},"NCT00196638","Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection",[40,41],"2006-03","2002-05",90,[14,1239],"Primary Acute Infection",[1221,1241],"Pegylated Interferon alpha",{"trials":1243,"activeCount":8},[],{"trials":1245,"activeCount":8},[],{"intervention":1241,"totalTrials":107,"cells":1247},{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1252,"PHASE3":1254,"PHASE4":1260,"NA":1262},{"trials":1249,"activeCount":8},[],{"trials":1251,"activeCount":8},[],{"trials":1253,"activeCount":8},[],{"trials":1255,"activeCount":8},[1256],{"nctId":1232,"briefTitle":1233,"status":62,"phases":1257,"completion":1235,"start":1236,"enrollment":1237,"conditions":1258,"interventions":1259},[40,41],[14,1239],[1221,1241],{"trials":1261,"activeCount":8},[],{"trials":1263,"activeCount":8},[],{"intervention":1265,"totalTrials":107,"cells":1266},"Yellow fever vaccination",{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1273,"PHASE4":1285,"NA":1287},{"trials":1268,"activeCount":8},[],{"trials":1270,"activeCount":8},[],{"trials":1272,"activeCount":8},[],{"trials":1274,"activeCount":8},[1275],{"nctId":1276,"briefTitle":1277,"status":141,"phases":1278,"primaryCompletion":1279,"completion":1280,"start":464,"enrollment":1281,"conditions":1282,"interventions":1284},"NCT01426243","The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.",[41],"2017-02","2017-12",71,[17,1283],"Yellow Fever",[1265,1265],{"trials":1286,"activeCount":8},[],{"trials":1288,"activeCount":8},[],{"intervention":1290,"totalTrials":107,"cells":1291},"Antiretroviral medications",{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1298,"PHASE4":1310,"NA":1312},{"trials":1293,"activeCount":8},[],{"trials":1295,"activeCount":8},[],{"trials":1297,"activeCount":8},[],{"trials":1299,"activeCount":8},[1300],{"nctId":1301,"briefTitle":1302,"status":141,"phases":1303,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1307,"interventions":1308},"NCT00495651","Early Antiretroviral Treatment and\u002For Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)",[41],"2015-01","2008-03",2073,[14,20],[1290,1309,1290,1309],"Antiretroviral medications+Isoniazid prophylaxis",{"trials":1311,"activeCount":8},[],{"trials":1313,"activeCount":8},[],{"intervention":1309,"totalTrials":107,"cells":1315},{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1322,"PHASE4":1328,"NA":1330},{"trials":1317,"activeCount":8},[],{"trials":1319,"activeCount":8},[],{"trials":1321,"activeCount":8},[],{"trials":1323,"activeCount":8},[1324],{"nctId":1301,"briefTitle":1302,"status":141,"phases":1325,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1326,"interventions":1327},[41],[14,20],[1290,1309,1290,1309],{"trials":1329,"activeCount":8},[],{"trials":1331,"activeCount":8},[],{"intervention":686,"totalTrials":107,"cells":1333},{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1340,"PHASE4":1346,"NA":1348},{"trials":1335,"activeCount":8},[],{"trials":1337,"activeCount":8},[],{"trials":1339,"activeCount":8},[],{"trials":1341,"activeCount":8},[1342],{"nctId":678,"briefTitle":679,"status":141,"phases":1343,"primaryCompletion":417,"completion":417,"start":681,"enrollment":682,"conditions":1344,"interventions":1345},[41],[14,29],[685,686,687],{"trials":1347,"activeCount":8},[],{"trials":1349,"activeCount":8},[],{"intervention":687,"totalTrials":107,"cells":1351},{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1356,"PHASE3":1358,"PHASE4":1364,"NA":1366},{"trials":1353,"activeCount":8},[],{"trials":1355,"activeCount":8},[],{"trials":1357,"activeCount":8},[],{"trials":1359,"activeCount":8},[1360],{"nctId":678,"briefTitle":679,"status":141,"phases":1361,"primaryCompletion":417,"completion":417,"start":681,"enrollment":682,"conditions":1362,"interventions":1363},[41],[14,29],[685,686,687],{"trials":1365,"activeCount":8},[],{"trials":1367,"activeCount":8},[],{"intervention":1369,"totalTrials":107,"cells":1370},"Interferon alfa-2b",{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1387,"NA":1389},{"trials":1372,"activeCount":8},[],{"trials":1374,"activeCount":8},[],{"trials":1376,"activeCount":8},[],{"trials":1378,"activeCount":8},[1379],{"nctId":1380,"briefTitle":1381,"status":62,"phases":1382,"completion":253,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1386},"NCT00125814","Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression",[41],"2001-12",200,[14],[1369],{"trials":1388,"activeCount":8},[],{"trials":1390,"activeCount":8},[],{"intervention":365,"totalTrials":107,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1405,"NA":1407},{"trials":1394,"activeCount":8},[],{"trials":1396,"activeCount":8},[],{"trials":1398,"activeCount":8},[],{"trials":1400,"activeCount":8},[1401],{"nctId":357,"briefTitle":358,"status":141,"phases":1402,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":1403,"interventions":1404},[41],[14,20],[284,365,366],{"trials":1406,"activeCount":8},[],{"trials":1408,"activeCount":8},[],{"intervention":1410,"totalTrials":107,"cells":1411},"Efavirenz-Tenofovir-Emtricitabine",{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1432,"NA":1434},{"trials":1413,"activeCount":8},[],{"trials":1415,"activeCount":8},[],{"trials":1417,"activeCount":8},[],{"trials":1419,"activeCount":8},[1420],{"nctId":1421,"briefTitle":1422,"status":1423,"phases":1424,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":8,"conditions":1428,"interventions":1430},"NCT00936195","Universal Use of EFV-TDF-FTC and AZT-3TC-LPV\u002Fr Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","WITHDRAWN",[41],"2013-01","2013-06","2010-01",[17,442,1429,14],"Breastfeeding",[1410,1431],"Zidovudine-Lamivudine-Lopinavir\u002FRitonavir",{"trials":1433,"activeCount":8},[],{"trials":1435,"activeCount":8},[],{"intervention":1431,"totalTrials":107,"cells":1437},{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1444,"PHASE4":1450,"NA":1452},{"trials":1439,"activeCount":8},[],{"trials":1441,"activeCount":8},[],{"trials":1443,"activeCount":8},[],{"trials":1445,"activeCount":8},[1446],{"nctId":1421,"briefTitle":1422,"status":1423,"phases":1447,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":8,"conditions":1448,"interventions":1449},[41],[17,442,1429,14],[1410,1431],{"trials":1451,"activeCount":8},[],{"trials":1453,"activeCount":8},[],{"intervention":1455,"totalTrials":47,"cells":1456},"Rituximab",{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1458,"activeCount":8},[],{"trials":1460,"activeCount":8},[],{"trials":1462,"activeCount":8},[1463,1471],{"nctId":1464,"briefTitle":1465,"status":62,"phases":1466,"completion":361,"start":262,"enrollment":1467,"conditions":1468,"interventions":1470},"NCT00127569","Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy",[40],25,[14,1469],"Giant Lymph Node Hyperplasia",[1455],{"nctId":1472,"briefTitle":1473,"status":62,"phases":1474,"completion":1475,"start":1476,"enrollment":1477,"conditions":1478,"interventions":1480},"NCT00126243","Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma",[40],"2003-10","1999-01",60,[1479],"AIDS Related Lymphoma",[1481,1482],"rituximab","CHOP",{"trials":1484,"activeCount":8},[],{"trials":1486,"activeCount":8},[],{"trials":1488,"activeCount":8},[],{"intervention":453,"totalTrials":47,"cells":1490},{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1510,"PHASE4":1512,"NA":1514},{"trials":1492,"activeCount":8},[],{"trials":1494,"activeCount":8},[],{"trials":1496,"activeCount":8},[1497,1506],{"nctId":1498,"briefTitle":1499,"status":141,"phases":1500,"primaryCompletion":307,"completion":307,"start":1501,"enrollment":1502,"conditions":1503,"interventions":1504},"NCT00528060","Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada",[40],"2008-01",35,[14],[453,346,1505],"Tenofovir\u002Femtricitabine",{"nctId":445,"briefTitle":446,"status":62,"phases":1507,"completion":448,"start":449,"enrollment":450,"conditions":1508,"interventions":1509},[40],[14],[335,453,346],{"trials":1511,"activeCount":8},[],{"trials":1513,"activeCount":8},[],{"trials":1515,"activeCount":8},[],{"intervention":1517,"totalTrials":47,"cells":1518},"Interleukin-2",{"EARLY_PHASE1":1519,"PHASE1":1521,"PHASE2":1523,"PHASE3":1540,"PHASE4":1542,"NA":1544},{"trials":1520,"activeCount":8},[],{"trials":1522,"activeCount":8},[],{"trials":1524,"activeCount":8},[1525,1533],{"nctId":1526,"briefTitle":1527,"status":141,"phases":1528,"primaryCompletion":520,"completion":1529,"start":241,"enrollment":1530,"conditions":1531,"interventions":1532},"NCT00113282","Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)",[40],"2008-02",57,[14],[1517],{"nctId":1534,"briefTitle":1535,"status":141,"phases":1536,"primaryCompletion":214,"completion":214,"start":1537,"enrollment":605,"conditions":1538,"interventions":1539},"NCT00120185","Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)",[40],"2003-12",[14],[1517],{"trials":1541,"activeCount":8},[],{"trials":1543,"activeCount":8},[],{"trials":1545,"activeCount":8},[],{"intervention":1547,"totalTrials":107,"cells":1548},"Valacyclovir",{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1563,"PHASE4":1565,"NA":1567},{"trials":1550,"activeCount":8},[],{"trials":1552,"activeCount":8},[],{"trials":1554,"activeCount":8},[1555],{"nctId":1556,"briefTitle":1557,"status":141,"phases":1558,"completion":64,"start":1559,"enrollment":1560,"conditions":1561,"interventions":1562},"NCT00158509","Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding",[40],"2004-08",215,[32,17],[1547],{"trials":1564,"activeCount":8},[],{"trials":1566,"activeCount":8},[],{"trials":1568,"activeCount":8},[],{"intervention":1570,"totalTrials":107,"cells":1571},"Acyclovir",{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1586,"PHASE4":1588,"NA":1590},{"trials":1573,"activeCount":8},[],{"trials":1575,"activeCount":8},[],{"trials":1577,"activeCount":8},[1578],{"nctId":1579,"briefTitle":1580,"status":141,"phases":1581,"completion":145,"start":262,"enrollment":1582,"conditions":1583,"interventions":1585},"NCT00158483","Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212)",[40],449,[1584,32],"Ulcer",[1570],{"trials":1587,"activeCount":8},[],{"trials":1589,"activeCount":8},[],{"trials":1591,"activeCount":8},[],{"intervention":1593,"totalTrials":107,"cells":1594},"rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1",{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1610,"PHASE4":1612,"NA":1614},{"trials":1596,"activeCount":8},[],{"trials":1598,"activeCount":8},[],{"trials":1600,"activeCount":8},[1601],{"nctId":1602,"briefTitle":1603,"status":141,"phases":1604,"primaryCompletion":1605,"completion":1605,"start":1127,"enrollment":1606,"conditions":1607,"interventions":1608},"NCT00651066","Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB\u002FHIV Co-infection in Vietnam",[40],"2012-09",47,[14,20],[1593,1609],"rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2",{"trials":1611,"activeCount":8},[],{"trials":1613,"activeCount":8},[],{"trials":1615,"activeCount":8},[],{"intervention":1609,"totalTrials":107,"cells":1617},{"EARLY_PHASE1":1618,"PHASE1":1620,"PHASE2":1622,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1619,"activeCount":8},[],{"trials":1621,"activeCount":8},[],{"trials":1623,"activeCount":8},[1624],{"nctId":1602,"briefTitle":1603,"status":141,"phases":1625,"primaryCompletion":1605,"completion":1605,"start":1127,"enrollment":1606,"conditions":1626,"interventions":1627},[40],[14,20],[1593,1609],{"trials":1629,"activeCount":8},[],{"trials":1631,"activeCount":8},[],{"trials":1633,"activeCount":8},[],{"intervention":1505,"totalTrials":107,"cells":1635},{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1640,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1637,"activeCount":8},[],{"trials":1639,"activeCount":8},[],{"trials":1641,"activeCount":8},[1642],{"nctId":1498,"briefTitle":1499,"status":141,"phases":1643,"primaryCompletion":307,"completion":307,"start":1501,"enrollment":1502,"conditions":1644,"interventions":1645},[40],[14],[453,346,1505],{"trials":1647,"activeCount":8},[],{"trials":1649,"activeCount":8},[],{"trials":1651,"activeCount":8},[],{"intervention":1653,"totalTrials":107,"cells":1654},"raltegravir potassium",{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1672,"PHASE4":1674,"NA":1676},{"trials":1656,"activeCount":8},[],{"trials":1658,"activeCount":8},[],{"trials":1660,"activeCount":8},[1661],{"nctId":1662,"briefTitle":1663,"status":141,"phases":1664,"primaryCompletion":1305,"completion":1665,"start":321,"enrollment":1666,"conditions":1667,"interventions":1668},"NCT00460382","Clinical Trial to Assess the Efficacy of Darunavir\u002FRitonavir (DRV\u002Fr), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses",[40],"2009-09",103,[14],[1653,1669,1670,1671],"darunavir\u002Fritonavir","etravirine","Optimized background regimen",{"trials":1673,"activeCount":8},[],{"trials":1675,"activeCount":8},[],{"trials":1677,"activeCount":8},[],{"intervention":1669,"totalTrials":107,"cells":1679},{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1684,"PHASE3":1690,"PHASE4":1692,"NA":1694},{"trials":1681,"activeCount":8},[],{"trials":1683,"activeCount":8},[],{"trials":1685,"activeCount":8},[1686],{"nctId":1662,"briefTitle":1663,"status":141,"phases":1687,"primaryCompletion":1305,"completion":1665,"start":321,"enrollment":1666,"conditions":1688,"interventions":1689},[40],[14],[1653,1669,1670,1671],{"trials":1691,"activeCount":8},[],{"trials":1693,"activeCount":8},[],{"trials":1695,"activeCount":8},[],{"intervention":1670,"totalTrials":107,"cells":1697},{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1708,"PHASE4":1710,"NA":1712},{"trials":1699,"activeCount":8},[],{"trials":1701,"activeCount":8},[],{"trials":1703,"activeCount":8},[1704],{"nctId":1662,"briefTitle":1663,"status":141,"phases":1705,"primaryCompletion":1305,"completion":1665,"start":321,"enrollment":1666,"conditions":1706,"interventions":1707},[40],[14],[1653,1669,1670,1671],{"trials":1709,"activeCount":8},[],{"trials":1711,"activeCount":8},[],{"trials":1713,"activeCount":8},[],{"intervention":1671,"totalTrials":107,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1717,"activeCount":8},[],{"trials":1719,"activeCount":8},[],{"trials":1721,"activeCount":8},[1722],{"nctId":1662,"briefTitle":1663,"status":141,"phases":1723,"primaryCompletion":1305,"completion":1665,"start":321,"enrollment":1666,"conditions":1724,"interventions":1725},[40],[14],[1653,1669,1670,1671],{"trials":1727,"activeCount":8},[],{"trials":1729,"activeCount":8},[],{"trials":1731,"activeCount":8},[],{"intervention":1733,"totalTrials":107,"cells":1734},"Lenalidomide",{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1736,"activeCount":8},[],{"trials":1738,"activeCount":8},[],{"trials":1740,"activeCount":8},[1741],{"nctId":1742,"briefTitle":1743,"status":62,"phases":1744,"primaryCompletion":416,"completion":416,"start":1745,"enrollment":1746,"conditions":1747,"interventions":1749},"NCT01282047","Lenalidomide in Kaposi Disease Associated With HIV Infection",[40],"2011-10",12,[1748],"HIV Infection Associated Kaposi Disease",[1733],{"trials":1751,"activeCount":8},[],{"trials":1753,"activeCount":8},[],{"trials":1755,"activeCount":8},[],{"intervention":1757,"totalTrials":107,"cells":1758},"7-valent pneumococcal conjugate vaccine",{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1773,"PHASE4":1775,"NA":1777},{"trials":1760,"activeCount":8},[],{"trials":1762,"activeCount":8},[],{"trials":1764,"activeCount":8},[1765],{"nctId":1766,"briefTitle":1767,"status":141,"phases":1768,"completion":361,"start":521,"enrollment":1769,"conditions":1770,"interventions":1771},"NCT00148824","Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.",[40],212,[14],[1757,1772],"23-valent pneumococcal conjugate vaccine",{"trials":1774,"activeCount":8},[],{"trials":1776,"activeCount":8},[],{"trials":1778,"activeCount":8},[],{"intervention":1772,"totalTrials":107,"cells":1780},{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1782,"activeCount":8},[],{"trials":1784,"activeCount":8},[],{"trials":1786,"activeCount":8},[1787],{"nctId":1766,"briefTitle":1767,"status":141,"phases":1788,"completion":361,"start":521,"enrollment":1769,"conditions":1789,"interventions":1790},[40],[14],[1757,1772],{"trials":1792,"activeCount":8},[],{"trials":1794,"activeCount":8},[],{"trials":1796,"activeCount":8},[],{"intervention":1798,"totalTrials":107,"cells":1799},"DNA vaccine pCMVS2.S",{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1814,"PHASE4":1816,"NA":1818},{"trials":1801,"activeCount":8},[],{"trials":1803,"activeCount":8},[],{"trials":1805,"activeCount":8},[1806],{"nctId":1807,"briefTitle":1808,"status":141,"phases":1809,"primaryCompletion":1810,"completion":1810,"start":1501,"enrollment":362,"conditions":1811,"interventions":1813},"NCT00536627","Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis",[39,40],"2010-11",[1812],"Chronic Hepatitis B",[1798],{"trials":1815,"activeCount":8},[],{"trials":1817,"activeCount":8},[],{"trials":1819,"activeCount":8},[],{"intervention":1821,"totalTrials":107,"cells":1822},"Fosamprenavir",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1838,"PHASE4":1840,"NA":1842},{"trials":1824,"activeCount":8},[],{"trials":1826,"activeCount":8},[],{"trials":1828,"activeCount":8},[1829],{"nctId":1830,"briefTitle":1831,"status":141,"phases":1832,"completion":240,"start":1833,"enrollment":1834,"conditions":1835,"interventions":1836},"NCT00122603","Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)",[40],"2005-12",61,[14],[1821,1837],"Saquinavir",{"trials":1839,"activeCount":8},[],{"trials":1841,"activeCount":8},[],{"trials":1843,"activeCount":8},[],{"intervention":1837,"totalTrials":107,"cells":1845},{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1847,"activeCount":8},[],{"trials":1849,"activeCount":8},[],{"trials":1851,"activeCount":8},[1852],{"nctId":1830,"briefTitle":1831,"status":141,"phases":1853,"completion":240,"start":1833,"enrollment":1834,"conditions":1854,"interventions":1855},[40],[14],[1821,1837],{"trials":1857,"activeCount":8},[],{"trials":1859,"activeCount":8},[],{"trials":1861,"activeCount":8},[],{"intervention":1863,"totalTrials":107,"cells":1864},"Proleukin",{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1866,"activeCount":8},[],{"trials":1868,"activeCount":8},[],{"trials":1870,"activeCount":8},[1871],{"nctId":1872,"briefTitle":1873,"status":141,"phases":1874,"primaryCompletion":1875,"completion":1876,"start":1305,"enrollment":1877,"conditions":1878,"interventions":1880},"NCT00574652","Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients",[39,40],"2010-03","2010-09",10,[1879],"Cryoglobulinemia Vasculitis",[1863],{"trials":1882,"activeCount":8},[],{"trials":1884,"activeCount":8},[],{"trials":1886,"activeCount":8},[],{"intervention":1888,"totalTrials":107,"cells":1889},"rifabutin in combination with efavirenz",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1891,"activeCount":8},[],{"trials":1893,"activeCount":8},[],{"trials":1895,"activeCount":8},[1896],{"nctId":1897,"briefTitle":1898,"status":141,"phases":1899,"primaryCompletion":1900,"completion":1900,"start":943,"enrollment":1901,"conditions":1902,"interventions":1903},"NCT00640887","Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB\u002FHIV Co-infection in South Africa",[40],"2010-10",48,[14,20],[1888,1904,1905],"rifabutin in combination with nevirapine","rifabutin in combination with lopinavir\u002Fritonavir",{"trials":1907,"activeCount":8},[],{"trials":1909,"activeCount":8},[],{"trials":1911,"activeCount":8},[],{"intervention":1904,"totalTrials":107,"cells":1913},{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1924,"PHASE4":1926,"NA":1928},{"trials":1915,"activeCount":8},[],{"trials":1917,"activeCount":8},[],{"trials":1919,"activeCount":8},[1920],{"nctId":1897,"briefTitle":1898,"status":141,"phases":1921,"primaryCompletion":1900,"completion":1900,"start":943,"enrollment":1901,"conditions":1922,"interventions":1923},[40],[14,20],[1888,1904,1905],{"trials":1925,"activeCount":8},[],{"trials":1927,"activeCount":8},[],{"trials":1929,"activeCount":8},[],{"intervention":1905,"totalTrials":107,"cells":1931},{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1933,"activeCount":8},[],{"trials":1935,"activeCount":8},[],{"trials":1937,"activeCount":8},[1938],{"nctId":1897,"briefTitle":1898,"status":141,"phases":1939,"primaryCompletion":1900,"completion":1900,"start":943,"enrollment":1901,"conditions":1940,"interventions":1941},[40],[14,20],[1888,1904,1905],{"trials":1943,"activeCount":8},[],{"trials":1945,"activeCount":8},[],{"trials":1947,"activeCount":8},[],{"intervention":1949,"totalTrials":107,"cells":1950},"maraviroc",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1952,"activeCount":8},[],{"trials":1954,"activeCount":8},[],{"trials":1956,"activeCount":8},[1957],{"nctId":1958,"briefTitle":1959,"status":141,"phases":1960,"primaryCompletion":1961,"completion":1962,"start":1665,"enrollment":1477,"conditions":1963,"interventions":1964},"NCT00944541","Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration",[40],"2010-08","2011-01",[17,14],[1949],{"trials":1966,"activeCount":8},[],{"trials":1968,"activeCount":8},[],{"trials":1970,"activeCount":8},[],{"intervention":208,"totalTrials":107,"cells":1972},{"EARLY_PHASE1":1973,"PHASE1":1975,"PHASE2":1977,"PHASE3":1983,"PHASE4":1985,"NA":1987},{"trials":1974,"activeCount":8},[],{"trials":1976,"activeCount":8},[],{"trials":1978,"activeCount":8},[1979],{"nctId":200,"briefTitle":201,"status":202,"phases":1980,"start":204,"enrollment":66,"conditions":1981,"interventions":1982},[40],[23,206],[208,190,209],{"trials":1984,"activeCount":8},[],{"trials":1986,"activeCount":8},[],{"trials":1988,"activeCount":8},[],{"intervention":209,"totalTrials":107,"cells":1990},{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":1995,"PHASE3":2001,"PHASE4":2003,"NA":2005},{"trials":1992,"activeCount":8},[],{"trials":1994,"activeCount":8},[],{"trials":1996,"activeCount":8},[1997],{"nctId":200,"briefTitle":201,"status":202,"phases":1998,"start":204,"enrollment":66,"conditions":1999,"interventions":2000},[40],[23,206],[208,190,209],{"trials":2002,"activeCount":8},[],{"trials":2004,"activeCount":8},[],{"trials":2006,"activeCount":8},[],{"intervention":219,"totalTrials":107,"cells":2008},{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2019,"PHASE4":2021,"NA":2023},{"trials":2010,"activeCount":8},[],{"trials":2012,"activeCount":8},[],{"trials":2014,"activeCount":8},[2015],{"nctId":211,"briefTitle":212,"status":141,"phases":2016,"completion":214,"start":215,"enrollment":216,"conditions":2017,"interventions":2018},[40],[14,26],[219,220,221],{"trials":2020,"activeCount":8},[],{"trials":2022,"activeCount":8},[],{"trials":2024,"activeCount":8},[],{"intervention":220,"totalTrials":107,"cells":2026},{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2037,"PHASE4":2039,"NA":2041},{"trials":2028,"activeCount":8},[],{"trials":2030,"activeCount":8},[],{"trials":2032,"activeCount":8},[2033],{"nctId":211,"briefTitle":212,"status":141,"phases":2034,"completion":214,"start":215,"enrollment":216,"conditions":2035,"interventions":2036},[40],[14,26],[219,220,221],{"trials":2038,"activeCount":8},[],{"trials":2040,"activeCount":8},[],{"trials":2042,"activeCount":8},[],{"intervention":234,"totalTrials":107,"cells":2044},{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2049,"PHASE3":2055,"PHASE4":2057,"NA":2059},{"trials":2046,"activeCount":8},[],{"trials":2048,"activeCount":8},[],{"trials":2050,"activeCount":8},[2051],{"nctId":223,"briefTitle":224,"status":141,"phases":2052,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":2053,"interventions":2054},[40],[231,232],[234,235,190],{"trials":2056,"activeCount":8},[],{"trials":2058,"activeCount":8},[],{"trials":2060,"activeCount":8},[],{"intervention":235,"totalTrials":107,"cells":2062},{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2064,"activeCount":8},[],{"trials":2066,"activeCount":8},[],{"trials":2068,"activeCount":8},[2069],{"nctId":223,"briefTitle":224,"status":141,"phases":2070,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":2071,"interventions":2072},[40],[231,232],[234,235,190],{"trials":2074,"activeCount":8},[],{"trials":2076,"activeCount":8},[],{"trials":2078,"activeCount":8},[],{"intervention":2080,"totalTrials":107,"cells":2081},"adjuvanted A(H1N1)v influenza vaccine",{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2099,"PHASE4":2101,"NA":2103},{"trials":2083,"activeCount":8},[],{"trials":2085,"activeCount":8},[],{"trials":2087,"activeCount":8},[2088],{"nctId":2089,"briefTitle":2090,"status":141,"phases":2091,"primaryCompletion":2092,"completion":2093,"start":2094,"enrollment":2095,"conditions":2096,"interventions":2097},"NCT01008813","Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)",[40],"2010-02","2010-12","2009-10",306,[14],[2080,2098],"non-adjuvanted A(H1N1)v influenza vaccine",{"trials":2100,"activeCount":8},[],{"trials":2102,"activeCount":8},[],{"trials":2104,"activeCount":8},[],{"intervention":2098,"totalTrials":107,"cells":2106},{"EARLY_PHASE1":2107,"PHASE1":2109,"PHASE2":2111,"PHASE3":2117,"PHASE4":2119,"NA":2121},{"trials":2108,"activeCount":8},[],{"trials":2110,"activeCount":8},[],{"trials":2112,"activeCount":8},[2113],{"nctId":2089,"briefTitle":2090,"status":141,"phases":2114,"primaryCompletion":2092,"completion":2093,"start":2094,"enrollment":2095,"conditions":2115,"interventions":2116},[40],[14],[2080,2098],{"trials":2118,"activeCount":8},[],{"trials":2120,"activeCount":8},[],{"trials":2122,"activeCount":8},[],{"intervention":2124,"totalTrials":107,"cells":2125},"vitamin D",{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2140,"PHASE4":2142,"NA":2144},{"trials":2127,"activeCount":8},[],{"trials":2129,"activeCount":8},[],{"trials":2131,"activeCount":8},[2132],{"nctId":2133,"briefTitle":2134,"status":141,"phases":2135,"primaryCompletion":2136,"completion":1425,"start":1810,"enrollment":2137,"conditions":2138,"interventions":2139},"NCT01226446","Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders",[40],"2012-02",32,[26],[2124],{"trials":2141,"activeCount":8},[],{"trials":2143,"activeCount":8},[],{"trials":2145,"activeCount":8},[],{"intervention":245,"totalTrials":107,"cells":2147},{"EARLY_PHASE1":2148,"PHASE1":2150,"PHASE2":2152,"PHASE3":2158,"PHASE4":2160,"NA":2162},{"trials":2149,"activeCount":8},[],{"trials":2151,"activeCount":8},[],{"trials":2153,"activeCount":8},[2154],{"nctId":237,"briefTitle":238,"status":141,"phases":2155,"completion":240,"start":241,"enrollment":242,"conditions":2156,"interventions":2157},[40],[23],[245,190,246],{"trials":2159,"activeCount":8},[],{"trials":2161,"activeCount":8},[],{"trials":2163,"activeCount":8},[],{"intervention":246,"totalTrials":107,"cells":2165},{"EARLY_PHASE1":2166,"PHASE1":2168,"PHASE2":2170,"PHASE3":2176,"PHASE4":2178,"NA":2180},{"trials":2167,"activeCount":8},[],{"trials":2169,"activeCount":8},[],{"trials":2171,"activeCount":8},[2172],{"nctId":237,"briefTitle":238,"status":141,"phases":2173,"completion":240,"start":241,"enrollment":242,"conditions":2174,"interventions":2175},[40],[23],[245,190,246],{"trials":2177,"activeCount":8},[],{"trials":2179,"activeCount":8},[],{"trials":2181,"activeCount":8},[],{"intervention":674,"totalTrials":107,"cells":2183},{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2194,"PHASE4":2196,"NA":2198},{"trials":2185,"activeCount":8},[],{"trials":2187,"activeCount":8},[],{"trials":2189,"activeCount":8},[2190],{"nctId":666,"briefTitle":667,"status":141,"phases":2191,"primaryCompletion":520,"completion":520,"start":669,"enrollment":670,"conditions":2192,"interventions":2193},[40],[672,14],[657,674],{"trials":2195,"activeCount":8},[],{"trials":2197,"activeCount":8},[],{"trials":2199,"activeCount":8},[],{"intervention":2201,"totalTrials":107,"cells":2202},"Amprenavir",{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2207,"PHASE3":2217,"PHASE4":2219,"NA":2221},{"trials":2204,"activeCount":8},[],{"trials":2206,"activeCount":8},[],{"trials":2208,"activeCount":8},[2209],{"nctId":2210,"briefTitle":2211,"status":141,"phases":2212,"completion":388,"start":2213,"enrollment":77,"conditions":2214,"interventions":2215},"NCT00196625","Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.",[40],"2000-11",[14],[2201,2216,346],"ABT-378\u002Fr",{"trials":2218,"activeCount":8},[],{"trials":2220,"activeCount":8},[],{"trials":2222,"activeCount":8},[],{"intervention":2216,"totalTrials":107,"cells":2224},{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2229,"PHASE3":2235,"PHASE4":2237,"NA":2239},{"trials":2226,"activeCount":8},[],{"trials":2228,"activeCount":8},[],{"trials":2230,"activeCount":8},[2231],{"nctId":2210,"briefTitle":2211,"status":141,"phases":2232,"completion":388,"start":2213,"enrollment":77,"conditions":2233,"interventions":2234},[40],[14],[2201,2216,346],{"trials":2236,"activeCount":8},[],{"trials":2238,"activeCount":8},[],{"trials":2240,"activeCount":8},[],{"intervention":2242,"totalTrials":107,"cells":2243},"IL-2",{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2260,"PHASE4":2262,"NA":2264},{"trials":2245,"activeCount":8},[],{"trials":2247,"activeCount":8},[],{"trials":2249,"activeCount":8},[2250],{"nctId":2251,"briefTitle":2252,"status":62,"phases":2253,"completion":2254,"start":2255,"enrollment":1477,"conditions":2256,"interventions":2257},"NCT00196651","HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection",[40],"2004-02","2000-08",[17],[2242,2258,2259],"LIPO-6T","ALVAC VIH 1433",{"trials":2261,"activeCount":8},[],{"trials":2263,"activeCount":8},[],{"trials":2265,"activeCount":8},[],{"intervention":2258,"totalTrials":107,"cells":2267},{"EARLY_PHASE1":2268,"PHASE1":2270,"PHASE2":2272,"PHASE3":2278,"PHASE4":2280,"NA":2282},{"trials":2269,"activeCount":8},[],{"trials":2271,"activeCount":8},[],{"trials":2273,"activeCount":8},[2274],{"nctId":2251,"briefTitle":2252,"status":62,"phases":2275,"completion":2254,"start":2255,"enrollment":1477,"conditions":2276,"interventions":2277},[40],[17],[2242,2258,2259],{"trials":2279,"activeCount":8},[],{"trials":2281,"activeCount":8},[],{"trials":2283,"activeCount":8},[],{"intervention":2259,"totalTrials":107,"cells":2285},{"EARLY_PHASE1":2286,"PHASE1":2288,"PHASE2":2290,"PHASE3":2296,"PHASE4":2298,"NA":2300},{"trials":2287,"activeCount":8},[],{"trials":2289,"activeCount":8},[],{"trials":2291,"activeCount":8},[2292],{"nctId":2251,"briefTitle":2252,"status":62,"phases":2293,"completion":2254,"start":2255,"enrollment":1477,"conditions":2294,"interventions":2295},[40],[17],[2242,2258,2259],{"trials":2297,"activeCount":8},[],{"trials":2299,"activeCount":8},[],{"trials":2301,"activeCount":8},[],{"intervention":1482,"totalTrials":107,"cells":2303},{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2314,"PHASE4":2316,"NA":2318},{"trials":2305,"activeCount":8},[],{"trials":2307,"activeCount":8},[],{"trials":2309,"activeCount":8},[2310],{"nctId":1472,"briefTitle":1473,"status":62,"phases":2311,"completion":1475,"start":1476,"enrollment":1477,"conditions":2312,"interventions":2313},[40],[1479],[1481,1482],{"trials":2315,"activeCount":8},[],{"trials":2317,"activeCount":8},[],{"trials":2319,"activeCount":8},[],{"intervention":2321,"totalTrials":107,"cells":2322},"LIPO-5",{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2337,"PHASE4":2339,"NA":2341},{"trials":2324,"activeCount":8},[],{"trials":2326,"activeCount":8},[],{"trials":2328,"activeCount":8},[2329],{"nctId":2330,"briefTitle":2331,"status":141,"phases":2332,"primaryCompletion":2333,"completion":520,"start":204,"enrollment":2334,"conditions":2335,"interventions":2336},"NCT00121758","AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers",[40],"2007-11",156,[14],[2321],{"trials":2338,"activeCount":8},[],{"trials":2340,"activeCount":8},[],{"trials":2342,"activeCount":8},[],{"intervention":2344,"totalTrials":107,"cells":2345},"HIV-1 gp 160",{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2358,"PHASE3":2360,"PHASE4":2362,"NA":2364},{"trials":2347,"activeCount":8},[],{"trials":2349,"activeCount":8},[2350],{"nctId":2351,"briefTitle":2352,"status":62,"phases":2353,"completion":669,"start":2354,"enrollment":9,"conditions":2355,"interventions":2356},"NCT00122564","Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers",[39],"2003-06",[14],[2344,2357],"DC-Chol",{"trials":2359,"activeCount":8},[],{"trials":2361,"activeCount":8},[],{"trials":2363,"activeCount":8},[],{"trials":2365,"activeCount":8},[],{"intervention":2357,"totalTrials":107,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2376,"PHASE3":2378,"PHASE4":2380,"NA":2382},{"trials":2369,"activeCount":8},[],{"trials":2371,"activeCount":8},[2372],{"nctId":2351,"briefTitle":2352,"status":62,"phases":2373,"completion":669,"start":2354,"enrollment":9,"conditions":2374,"interventions":2375},[39],[14],[2344,2357],{"trials":2377,"activeCount":8},[],{"trials":2379,"activeCount":8},[],{"trials":2381,"activeCount":8},[],{"trials":2383,"activeCount":8},[],{"intervention":2385,"totalTrials":107,"cells":2386},"Lipopeptides LIPO-4",{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2398,"PHASE3":2400,"PHASE4":2402,"NA":2404},{"trials":2388,"activeCount":8},[],{"trials":2390,"activeCount":8},[2391],{"nctId":2392,"briefTitle":2393,"status":141,"phases":2394,"completion":1833,"start":448,"enrollment":362,"conditions":2395,"interventions":2397},"NCT00121121","Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers",[39],[14,2396],"HIV Seronegativity",[2385],{"trials":2399,"activeCount":8},[],{"trials":2401,"activeCount":8},[],{"trials":2403,"activeCount":8},[],{"trials":2405,"activeCount":8},[],{"intervention":346,"totalTrials":191,"cells":2407},{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2430,"PHASE4":2440,"NA":2442},{"trials":2409,"activeCount":8},[],{"trials":2411,"activeCount":8},[],{"trials":2413,"activeCount":8},[2414,2418,2422,2426],{"nctId":1498,"briefTitle":1499,"status":141,"phases":2415,"primaryCompletion":307,"completion":307,"start":1501,"enrollment":1502,"conditions":2416,"interventions":2417},[40],[14],[453,346,1505],{"nctId":384,"briefTitle":385,"status":62,"phases":2419,"completion":387,"start":388,"enrollment":332,"conditions":2420,"interventions":2421},[40],[14],[347,313,346],{"nctId":2210,"briefTitle":2211,"status":141,"phases":2423,"completion":388,"start":2213,"enrollment":77,"conditions":2424,"interventions":2425},[40],[14],[2201,2216,346],{"nctId":445,"briefTitle":446,"status":62,"phases":2427,"completion":448,"start":449,"enrollment":450,"conditions":2428,"interventions":2429},[40],[14],[335,453,346],{"trials":2431,"activeCount":8},[2432,2436],{"nctId":1124,"briefTitle":1125,"status":141,"phases":2433,"primaryCompletion":1127,"completion":1128,"start":143,"enrollment":1129,"conditions":2434,"interventions":2435},[41],[14],[1113,1132],{"nctId":338,"briefTitle":339,"status":141,"phases":2437,"completion":331,"start":341,"enrollment":342,"conditions":2438,"interventions":2439},[41],[14],[345,313,312,346,347],{"trials":2441,"activeCount":8},[],{"trials":2443,"activeCount":8},[2444],{"nctId":2445,"briefTitle":2446,"status":62,"phases":2447,"completion":2448,"start":2449,"enrollment":2450,"conditions":2451,"interventions":2452},"NCT00122590","Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)",[43],"2005-03","2002-07",115,[14],[2453,2454,2455,1132],"nelfinavir","lopinavir\u002Fr","indinavir",{"intervention":347,"totalTrials":33,"cells":2457},{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2462,"PHASE3":2468,"PHASE4":2474,"NA":2476},{"trials":2459,"activeCount":8},[],{"trials":2461,"activeCount":8},[],{"trials":2463,"activeCount":8},[2464],{"nctId":384,"briefTitle":385,"status":62,"phases":2465,"completion":387,"start":388,"enrollment":332,"conditions":2466,"interventions":2467},[40],[14],[347,313,346],{"trials":2469,"activeCount":8},[2470],{"nctId":338,"briefTitle":339,"status":141,"phases":2471,"completion":331,"start":341,"enrollment":342,"conditions":2472,"interventions":2473},[41],[14],[345,313,312,346,347],{"trials":2475,"activeCount":8},[],{"trials":2477,"activeCount":8},[2478],{"nctId":2445,"briefTitle":2446,"status":62,"phases":2479,"completion":2448,"start":2449,"enrollment":2450,"conditions":2480,"interventions":2481},[43],[14],[2453,2454,2455,1132],{"intervention":2483,"totalTrials":107,"cells":2484},"blood test: rapid finger-stick blood specimen test",{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2486,"activeCount":8},[],{"trials":2488,"activeCount":8},[],{"trials":2490,"activeCount":8},[],{"trials":2492,"activeCount":8},[],{"trials":2494,"activeCount":8},[],{"trials":2496,"activeCount":8},[2497],{"nctId":2498,"briefTitle":2499,"status":141,"phases":2500,"primaryCompletion":1064,"completion":1064,"start":1875,"enrollment":2501,"conditions":2502,"interventions":2503},"NCT01164462","Feasibility and Limitations of Offering Community Based Rapid HIV Testing to Men Who Have Sex With Men (MSM)",[43],357,[14],[2483,2504],"blood test: conventional test",{"intervention":2504,"totalTrials":107,"cells":2506},{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2513,"PHASE4":2515,"NA":2517},{"trials":2508,"activeCount":8},[],{"trials":2510,"activeCount":8},[],{"trials":2512,"activeCount":8},[],{"trials":2514,"activeCount":8},[],{"trials":2516,"activeCount":8},[],{"trials":2518,"activeCount":8},[2519],{"nctId":2498,"briefTitle":2499,"status":141,"phases":2520,"primaryCompletion":1064,"completion":1064,"start":1875,"enrollment":2501,"conditions":2521,"interventions":2522},[43],[14],[2483,2504],{"intervention":2524,"totalTrials":107,"cells":2525},"Peripheral blood biological tests",{"EARLY_PHASE1":2526,"PHASE1":2528,"PHASE2":2530,"PHASE3":2532,"PHASE4":2534,"NA":2536},{"trials":2527,"activeCount":8},[],{"trials":2529,"activeCount":8},[],{"trials":2531,"activeCount":8},[],{"trials":2533,"activeCount":8},[],{"trials":2535,"activeCount":8},[],{"trials":2537,"activeCount":8},[2538],{"nctId":2539,"briefTitle":2540,"status":141,"phases":2541,"primaryCompletion":2542,"completion":2543,"start":2544,"enrollment":1384,"conditions":2545,"interventions":2548},"NCT01038999","Accelerated Aging, HIV Infection, Antiretroviral Therapies",[],"2010-04","2012-03","2009-04",[17,2546,2547],"Aging Accelerated","Antiretroviral Therapies",[2524],{"intervention":2550,"totalTrials":107,"cells":2551},"blood sampling, specific biological exams and biobank and self administered questionnaires",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2558,"PHASE4":2560,"NA":2562},{"trials":2553,"activeCount":8},[],{"trials":2555,"activeCount":8},[],{"trials":2557,"activeCount":8},[],{"trials":2559,"activeCount":8},[],{"trials":2561,"activeCount":8},[],{"trials":2563,"activeCount":8},[2564],{"nctId":2565,"briefTitle":2566,"status":141,"phases":2567,"primaryCompletion":2568,"completion":2569,"start":1127,"enrollment":2570,"conditions":2571,"interventions":2573},"NCT01269632","Cohort of Young Adults Infected With HIV Since Birth or During Childhood",[43],"2018-12","2018-12-27",469,[17,2572],"Young Adult",[2550],{"intervention":2575,"totalTrials":107,"cells":2576},"A single blood sample",{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2581,"PHASE3":2583,"PHASE4":2585,"NA":2587},{"trials":2578,"activeCount":8},[],{"trials":2580,"activeCount":8},[],{"trials":2582,"activeCount":8},[],{"trials":2584,"activeCount":8},[],{"trials":2586,"activeCount":8},[],{"trials":2588,"activeCount":8},[2589],{"nctId":2590,"briefTitle":2591,"status":141,"phases":2592,"primaryCompletion":943,"completion":943,"start":2593,"enrollment":2594,"conditions":2595,"interventions":2596},"NCT01055873","Immunology of the Infection Perinatal",[],"2007-02",93,[14],[2575],{"intervention":2453,"totalTrials":107,"cells":2598},{"EARLY_PHASE1":2599,"PHASE1":2601,"PHASE2":2603,"PHASE3":2605,"PHASE4":2607,"NA":2609},{"trials":2600,"activeCount":8},[],{"trials":2602,"activeCount":8},[],{"trials":2604,"activeCount":8},[],{"trials":2606,"activeCount":8},[],{"trials":2608,"activeCount":8},[],{"trials":2610,"activeCount":8},[2611],{"nctId":2445,"briefTitle":2446,"status":62,"phases":2612,"completion":2448,"start":2449,"enrollment":2450,"conditions":2613,"interventions":2614},[43],[14],[2453,2454,2455,1132],{"intervention":2454,"totalTrials":107,"cells":2616},{"EARLY_PHASE1":2617,"PHASE1":2619,"PHASE2":2621,"PHASE3":2623,"PHASE4":2625,"NA":2627},{"trials":2618,"activeCount":8},[],{"trials":2620,"activeCount":8},[],{"trials":2622,"activeCount":8},[],{"trials":2624,"activeCount":8},[],{"trials":2626,"activeCount":8},[],{"trials":2628,"activeCount":8},[2629],{"nctId":2445,"briefTitle":2446,"status":62,"phases":2630,"completion":2448,"start":2449,"enrollment":2450,"conditions":2631,"interventions":2632},[43],[14],[2453,2454,2455,1132],{"intervention":2634,"totalTrials":107,"cells":2635},"naso-pharyngeal swab",{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2642,"PHASE4":2644,"NA":2646},{"trials":2637,"activeCount":8},[],{"trials":2639,"activeCount":8},[],{"trials":2641,"activeCount":8},[],{"trials":2643,"activeCount":8},[],{"trials":2645,"activeCount":8},[],{"trials":2647,"activeCount":8},[2648],{"nctId":2649,"briefTitle":2650,"status":141,"phases":2651,"primaryCompletion":1810,"completion":1810,"start":417,"enrollment":2652,"conditions":2653,"interventions":2655},"NCT01039220","Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients",[43],1266,[14,2654],"Influenza",[2634],{"intervention":2657,"totalTrials":107,"cells":2658},"blood test at day one",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2660,"activeCount":8},[],{"trials":2662,"activeCount":8},[],{"trials":2664,"activeCount":8},[],{"trials":2666,"activeCount":8},[],{"trials":2668,"activeCount":8},[],{"trials":2670,"activeCount":8},[2671],{"nctId":2672,"briefTitle":2673,"status":141,"phases":2674,"primaryCompletion":2675,"completion":2543,"start":273,"enrollment":2676,"conditions":2677,"interventions":2678},"NCT01065207","Patients Infected With HIV Since More Than 10 Years With a Plasma Viral RNA \u003C400 Copies \u002F mL in the Absence of Any Treatment: Study Mechanisms Involved in Controlling the Infection",[43],"2011-03",250,[17],[2657],{"intervention":2680,"totalTrials":107,"cells":2681},"blood and semen sampling, specific biological exams and biobank and self administered questionnaires",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2683,"activeCount":8},[],{"trials":2685,"activeCount":8},[],{"trials":2687,"activeCount":8},[],{"trials":2689,"activeCount":8},[],{"trials":2691,"activeCount":8},[],{"trials":2693,"activeCount":8},[2694],{"nctId":2695,"briefTitle":2696,"status":141,"phases":2697,"primaryCompletion":2136,"completion":2543,"start":464,"enrollment":2698,"conditions":2699,"interventions":2700},"NCT01413152","Residual Risk Assessment Of HIV Transmission",[43],167,[17],[2680]]